Hanmi Pharm’s partner Spectrum said in a press release on first quarter results published on the 9th (local time) that Hanmi Pharm’s neutropenia treatment ‘Rolvedon’ (Korean name: Rolontis) grew by 54% from the quarter previous to $15.6 million ( He earned about 206 million. He announced on the 15th that he had achieved net sales of 100 million won).
According to Spectrum, the number of Rollbedon buying partners and sales / distribution networks increased from 70 in the fourth quarter of last year to 172 in the first quarter of this year. In particular, since last April, with the application of J-code J1449 for permanent reimbursement, it has been listed on the US public insurance reimbursement drug list, creating a more stable prescription environment.
In this performance announcement, Spectrum once again disclosed the fact that it has signed a merger agreement with Assertio, a pharmaceutical company specializing in non-face-to-face sales marketing that provides differentiated products to patients using a platform digital. The merger process between the two companies will continue until the third quarter of this year.
“The combination of Spectrum’s commercial infrastructure and Assaultio’s digital resources will lay the foundation for long-term growth, and we expect Rollbedon’s revenue to grow even faster,” said Spectrum President Tom Riga.
